Keytruda pembrolizumab: Preliminary Phase II data

Preliminary data from 50 evaluable patients with recurrent or metastatic SCCHN who progressed on platinum-based therapy and cetuximab in the open-label Phase II KEYNOTE-055 trial showed that 200 mg IV...